The combination of bronchial asthma with pathology of the digestive tract--one of the most frequent, clinically diverse and difficult, which complicates its course. The prevalence of gastroesophageal reflux disease in patients with asthma ranged from 33 to 90%. Aggravation of GERD is considered as one of the triggers of asthma attacks. The basis for treatment of GERD is acid suppression. Select proton pump inhibitors as the primary means of therapy related to their antisecretory action. Among the PPI pantoprazole can be identified that has high bioavailability, has minimal drug interactions with other drugs and a favorable safety profile. In patients taking pantoprazole pH-metry approached the norm, the proportion of time with pH < 4 decreased from 2 h 31 min to 52 min. On the background of pantoprazole indicators of lung function were better and significantly higher than in the groupwith omeprazole. Patients with combined pathology requiring compulsory treatment concomitant GERD, which will improve the course of asthma and help to achieve control.